Author(s): Hari Prasad Sonwani* and Aakanksha Sinha
Because of the elevated pulmonary vascular resistance and arterial hypoxemia caused by acute pulmonary embolism, right heart failure may result. It is imperative that pulmonary hypertension patients receive effective vasodilator therapy. Thus, using a rabbit model of acute pulmonary embolism, we examined the effects of a recently created, potent pulmonary vasodilator called organic mononitrates of 1,2-propanediol (PDNO). Blood gases, plasma nitrite content, exhaled Nitric Oxide (NO), and systemic and pulmonary hemodynamics were measured in anesthetized and ventilated rabbits. PDNO and inorganic nitrite were infused intravenously and into the left ventricle of naive animals, as well as in animals with pulmonary hypertension caused by a thromboxane A2 analogue, in doseresponse tests. Second, an acute pulmonary embolism was created, and after 20 minutes, either PDNO or a placebo was injected intravenously and assessed within after pulmonary embolization by one hour. Compared to inorganic nitrite given intravenously, PDNO showed effective NO donation by increasing exhaled NO, reducing pulmonary hypertension, and dose-dependently vasodilating the systemic circulation. Gas exchange disruptions and pulmonary hypertension were brought on by pulmonary embolization. Without causing tolerance, PDNO significantly reduced and stabilized the right ventricular rate-pressure product and pulmonary vascular resistance. It also had no notable side effects on methemoglobin generation, blood-gas values, or the systemic circulation. To sum up, in the pulmonary circulation, PDNO functions as both an effective vasodilator and a donor of NO. In the event of a life-threatening acute pulmonary embolism, intravenous treatment with this or comparable organic nitrites may be the future of treatment to prevent right heart failure.
